Summary Seventeen Thoroughbred horses with moderate to severe gastric ulceration were purchased from a race track within 10 days of racing and were treated once daily with either omeprazole (9 horses) or vehicle (8 horses) and evaluated gastroscopically for ulcer healing. Horses were administered omeprazole (1.5 mg/kg bwt/day) or vehicle by nasogastric tube once daily. Gastroscopic examination was performed on Days 0, 4, 7, 11, 14, 17, 21, 24 and 28, until lesions healed completely. Selected images of gastric lesions were captured by computer at each endoscopic examination, with a measuring caliper included in captured images. The area and perimeter of lesions were measured by computer and healing rates of specific lesions were determined by calculating the rate of linear advance of the margins toward the centre of the lesion. Additionally, the number of days to complete healing of the entire gastric squamous mucosa was compared between treatment groups. Gastric lesions healed at a significantly faster rate in horses receiving omeprazole than in vehicle‐treated horses (P<0.001). Complete healing of the entire stomach occurred in 10–21 days in omeprazole‐treated horses, and 14–28 days in 3 of 8 vehicle‐treated horses, with the remaining vehicle‐treated horses having unhealed lesions on Day 28. In addition, 5 vehicle‐treated horses developed new lesions in the squamous epithelial mucosa during the trial; no new lesions were observed in the omeprazole‐treated group.

Summary Whole blood and serum were collected from foals to determine the prevalence of Equine herpesvirus type 2 (EHV2) infection in foals, age at which infection can first be identified and serological responses to infection. Equine herpesvirus type 2 was isolated from peripheral blood mononuclear cells (PBMC) from 68 of 69 foals, 1–8‐months‐old, sampled once. Virus isolation was performed twice at intervals of 2–7 months on PBMCs from 33 foals and EHV2 was isolated on both occasions in all but one foal (negative, then positive). Regression analysis of log2‐transformed reciprocal serum EHV2 virus neutralising (VN) titres revealed that in foals age 1–7 months, EHV2 VN antibody titre was positively correlated with age (r = 0.94). Paired serum samples were obtained from 58 foals, with the first samples collected age 1–6 months and the second samples collected 2–4 months later. There were significant (P<0.05) increases in mean VN titres to EHV2 in foals sampled initially at age 1–4. Eight foals had blood sampled prior to sucking and at age 7, 20, 30 and 45 days. Each foal was negative for EHV2 in PBMC and each foal had a negative serum EHV2 VN titre immediately after birth. Each foal was positive for EHV2 in PBMC by age 45 days, with the earliest isolation at 25 days. Tracheal aspirate fluid and peripheral blood were collected from 20 foals without clinical signs of respiratory disease and from 30 foals with clinical signs of lower respiratory disease. In 20 foals without clinical signs of respiratory disease, EHV2 was isolated from tracheal aspirates (1/20 foals) and PBMC (20/20 foals) and in 30 foals with such clinical signs, from trachea aspirates (20/30 foals: P<0.01) and from PBMC (30/30 foals). In one 6‐month‐old foal, EHV1, but not EHV2, was isolated from the tracheal aspirate, 3 months after EHV2 had been isolated from a tracheal aspirate. These results demonstrate a greater prevalence of EHV2 in lower respiratory secretions in foals with clinically apparent lower respiratory disease, but a cause and effect relationship between the virus and lower respiratory disease remains to be elucidated. It is noteworthy, however, that of virus isolations performed on 50 tracheal aspirates, a virus (EHV1) other than EHV2 was isolated only once.